FX.Bosch et al, including the CoheaHr consortium, have published an open access opinion piece in Nature Reviews Clinical Oncology: “HPV-FASTER: broadening the scope for prevention of HPV-related cancer” – a proposal for the integration of screening and vaccination programmes, including an extention of routine vaccination programmes to older women.
Archives for 2015
The 30th International Papillomavirus Conference is taking place in Lisbon, Portugal, from September 17th-21st. The CoheaHr consortium is well represented and partners actively participate as presenters, chairpersons and workshop leaders. Here, you can find a list of selected conference proceedings related to CoheaHr: HPV2015_Lisbon_CoheaHr
The Belgium Health Care Knowledge Centre (KCE) is a federal scientific organisation that aims to advise policymakers on decisions relating to health care and health insurance – on the basis of scientific analysis and research.
The Health Technology Assessment (HTA) unit of KCE has recently published its report on HPV primary screening. The report can be downloaded from KCE’s website at: https://kce.fgov.be
Following a paper on the HPV-type specific long-term risk for cytological abnormalities (Elfstrom et al), the same group has now published the HPV-type specific long-term risk for CIN2 and CIN3.
In this paper they report substantial differences in risks for CIN2 and CIN3 between different oncogenic types. The highest cumulative incidence – after 14 years of follow-up, was recorded for HPV16/18/31/33 – with a cumulative incidence for CIN3+ of above 28%. The increased risk compared to HPV negative women was highest during the initial screening round – but remained high throughout follow-up. This implies that prolonged follow-up of women positive for certain HPV types may be warranted. The quantified differences of type-specific CIN risk will be useful for the development of risk-stratified screening algorithms.
Smelov V, Elfström KM, Johansson AL et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer. 2015 Mar 1;136(5):1171-80